Adhesive and molecular friction in tribological conjunctions

This thesis investigates the underlying causes of friction and ine ciency within an internal combustion engine, focusing on the ring-liner conjunction in the vicinity of the power-stroke top dead centre reversal. In such lubricated contacts, friction is the result of the interplay between numerous kinetics, with those at micro- and nano-scale interactions being signi cantly di erent than the ones at larger scales. A modi ed Elrod's cavitation algorithm is developed to determine the microscopic tribological characteristics of the piston ring-liner contact. Predicting lubricant tran- sient behaviour is critical when the inlet reversal leads to thin lms and inherent metal-to-metal interaction. The model clearly shows that cavitation at the trailing edge of the ring-liner contact generated pre-reversal, persists after reversal and pro- motes starvation and depletion of the oil lm. Hence, this will lead to boundary friction. A fractal based boundary friction model is developed for lightly loaded asperity con- tacts, separated by diminishing small lms, usually wetted by a layer of molecules adsorbed to the tips of the asperities. In nano-scale conjunctions, a lubricant layering e ect often takes place due to the smoothness of surfaces, which is governed by the surface and lubricant properties. A molecularly thin layer of lubricant molecules can adhere to the asperities, being the last barrier against direct surface contact. As a result, boundary friction (prevailing in such diminishing gaps) is actually determined by a combination of shearing of a thin adsorbed lm, adhesion of approaching as- perities and their plastic deformation. A model for physio-chemical hydrodynamic mechanism is successfully established, describing the formation of thin adsorbed lms between asperities. This model is e ectively integrated with separately devel- oped models that predict the adhesive and plastic contact of asperities.EThOS - Electronic Theses Online ServiceGBUnited Kingdo

A Survey of Empirical Results on Program Slicing

International audienceBACKGROUND:Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.METHODS:This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants.FINDINGS:Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043).INTERPRETATION:Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding